Divyaveer Smita, Kashyap Madhuri, Kekan Kushal, Yadav Ashok K, Kaur Jaskiran, Premkumar Madhumita, Gandotra Akash, Prajapati Kanchan, De Arka, Duseja Ajay K, Verma Nipun, Aggarwal Radhika, Venkatasubramanian Vaishnavi, Tiwari Vaibhav, Bagur Vishnuvardhan, Patil Amol N, Safiq Nusrat, Kohli Harbir S
Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Experimental Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102464. doi: 10.1016/j.jceh.2024.102464. Epub 2024 Nov 22.
Renal impairment significantly affects morbidity and mortality rates of cirrhosis patients. Studies on glomerular filtration rate (eGFR) estimation did not include cirrhosis patients. These equations are erroneous and unreliable in cirrhosis due to sarcopenia. Further, the accuracy of eGFR equations varies across different ethnic groups. Measurement of GFR by iohexol clearance is a gold standard method of accurate determination of GFR. There is scarce data on iohexol GFR in cirrhosis and none in Indian population.
This was prospective observational study. Consecutive adult patients with cirrhosis with stable renal function for prior 1 month were included. Iohexol weight-based dosage was given and timed blood samples were taken to measure iohexol clearance. Plasma iohexol levels was measured by high performance liquid chromatography (HPLC) and Cystatin-C was measured by ELISA in plasma samples.
Thirty-five patients were enrolled in the study. Hepatitis B (n = 5), hepatitis C (n = 4); alcoholic liver disease (n = 20), metabolic dysfunctional associated steatotic liver disease (n = 2), others/overlap (n = 3). The average eGFR by MDRD4, MDRD6, CKD-EPI Creat, CKD EPI Cys C, CKD EPI Creat-Cys C, RFHand GRAIL formulae were 105.24(24.2),104.75(23.5),102.14(15.9),68.91(16.5),82.91(15.21), 67.27 (14.08) and 112.9 (19.5) ml/min ml/min/1.73m, respectively. The average mGFR measured by iohexol method was 73.44 (16.8)ml/min/1.73 m. 30% agreement with mGFR was found with eGFR by MDRD4 in 38.2% (n = 13), MDRD6 38.2% ((n = 13), CKD-EPI Creat in 35.2% (n = 12), CKD EPI Cys C in 79.41% (n = 27), CKD EPI Creat-Cys C in 76.42% (n = 26), RFH 76.4% (n = 26) and GRAIL 20.5% (n = 7).
The eGFR equations using creatinine are imprecise and less accurate in Indian patients with cirrhosis. All equations overestimate GFR. Equations especially developed for cirrhosis patients like MDRD6 are also not precise. Cystatin C based equations are better than creatinine-based equations. Further studies with large sample size are needed to establish an accurate method of GFR assessment in Indian patients with cirrhosis.
肾功能损害显著影响肝硬化患者的发病率和死亡率。关于肾小球滤过率(eGFR)估算的研究未纳入肝硬化患者。由于肌肉减少症,这些公式在肝硬化患者中存在误差且不可靠。此外,eGFR公式的准确性在不同种族群体中有所差异。通过碘海醇清除率测量肾小球滤过率是准确测定肾小球滤过率的金标准方法。关于肝硬化患者碘海醇肾小球滤过率的数据稀缺,而印度人群中尚无此类数据。
这是一项前瞻性观察性研究。纳入连续1个月肾功能稳定的成年肝硬化患者。给予基于体重的碘海醇剂量,并采集定时血样以测量碘海醇清除率。血浆碘海醇水平通过高效液相色谱法(HPLC)测量,血浆样本中的胱抑素C通过酶联免疫吸附测定法(ELISA)测量。
35例患者纳入研究。乙型肝炎(n = 5),丙型肝炎(n = 4);酒精性肝病(n = 20),代谢功能障碍相关脂肪性肝病(n = 2),其他/重叠(n = 3)。MDRD4、MDRD6、CKD - EPI Creat、CKD EPI Cys C、CKD EPI Creat - Cys C、RFH和GRAIL公式计算的平均eGFR分别为105.24(24.2)、104.75(23.5)、102.14(15.9)、68.91(16.5)、82.91(15.21)、67.27(14.08)和112.9(19.5)ml/min/1.73m²。通过碘海醇法测量的平均mGFR为73.44(16.8)ml/min/1.73m²。MDRD4的eGFR与mGFR的一致性为38.2%(n = 13),MDRD6为38.2%(n = 13),CKD - EPI Creat为35.2%(n = 12),CKD EPI Cys C为79.41%(n = 27),CKD EPI Creat - Cys C为76.42%(n = 26),RFH为76.4%(n = 26),GRAIL为20.5%(n = 7)。
在印度肝硬化患者中,使用肌酐的eGFR公式不精确且准确性较差。所有公式均高估了肾小球滤过率。专门为肝硬化患者开发的公式如MDRD6也不精确。基于胱抑素C的公式优于基于肌酐的公式。需要进一步进行大样本研究以建立印度肝硬化患者肾小球滤过率评估的准确方法。